CEO Bahija Jallal was paid $10,885,268 in fiscal year 2025, ↓ down 15.3% from fiscal year 2024, the 79th percentile of its disclosed peer group (SEC filing 0001140361-26-015122 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$10,885,268 ↓ Bahija Jallal total, FY2025 | 79th CEO pay percentile vs peers | 92:1 CEO-to-median pay ratio | 77.54% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
IMCR's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Bahija Jallal | $765,000 | $0 | $2,819,992 | $6,579,990 | $688,500 | $0 | $31,786 | $10,885,268 |
| Chief Executive Officer | ||||||||
| Travis Coy | 500,000 | 100,000 | 0 | 4,299,989 | 250,000 | 0 | 21,220 | 5,171,209 |
| Chief Financial Officer and Head of Corporate Development | ||||||||
| David Berman | 540,000 | 0 | 1,399,991 | 2,099,992 | 216,000 | 0 | 23,005 | 4,278,988 |
| Former Executive Vice President, Head of Research & Development | ||||||||
| Tina St. Leger | 374,946 | 0 | 250,890 | 376,357 | 179,974 | 0 | 23,150 | 1,204,261 |
| Chief Human Resources Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Bahija Jallal | $10,885,268 | $12,852,234 | $11,678,834 | ↓ −1,966,966 |
| Travis Coy | 5,171,209 | — | — | — |
| David Berman | 4,278,988 | 5,481,495 | 4,396,622 | ↓ −1,202,507 |
| Tina St. Leger | 1,204,261 | 1,115,871 | 1,039,117 | ↑ +88,390 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Immunocore Holdings's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper IMCR reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name IMCR as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Kristine Peterson | Independent Director | $472,532 |
| Professor Sir John Bell | Chair of the Board | $498,943 |
| Professor Sir Peter Ratcliffe | Independent Director | $464,991 |
| Ranjeev Krishana | Former director (through FY2025) | $451,977 |
| Robert Perez | Former director (through FY2025) | — |
| Roy S. Herbst | Independent Director | $471,419 |
| Siddharth Kaul | Independent Director | $477,491 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Roy S. Herbst | Director | 2026-05-27 | A | 27,492 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Professor Sir John Bell | Director | 2026-05-27 | A | 27,492 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Siddharth Kaul | Director | 2026-05-27 | A | 27,492 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Professor Sir Peter Ratcliffe | Director | 2026-05-27 | A | 27,492 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Pao | Director | 2026-05-27 | A | 27,492 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristine Peterson | Director | 2026-05-27 | A | 27,492 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Berman | RSU | 2025-02-17 | — | — | 47,297 | — | $1,399,991 |
| Bahija Jallal | RSU | 2025-02-17 | — | — | 95,270 | — | 2,819,992 |
| Tina St. Leger | RSU | 2025-02-17 | — | — | 8,476 | — | 250,889 |
| Bahija Jallal | OPTION | 2025-02-17 | — | — | 405,824 | — | 6,579,990 |
| Travis Coy | OPTION | 2025-01-01 | — | — | 274,033 | — | 4,299,989 |
| David Berman | OPTION | 2025-02-17 | — | — | 129,518 | — | 2,099,992 |
| Tina St. Leger | OPTION | 2025-02-17 | — | — | 23,212 | — | 376,357 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Berman | $1,399,991 | $0 | $2,099,992 | 0.0% |
| Bahija Jallal | 2,819,992 | 0 | 6,579,990 | 0.0% |
| Tina St. Leger | 250,889 | 0 | 376,357 | 0.0% |
| Travis Coy | 0 | 0 | 4,299,989 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bahija Jallal | Option | 81,004 | 64.53 | — |
| Bahija Jallal | RSU | 95,270 | — | 3,306,822 |
| David Berman | RSU | 47,297 | — | 1,641,679 |
| Tina St. Leger | RSU | 8,476 | — | 294,202 |
| Bahija Jallal | Option | 27,849 | 24.66 | — |
| Bahija Jallal | Option | 158,523 | 70.5 | — |
| Bahija Jallal | Option | 405,824 | 29.6 | — |
| Travis Coy | Option | 274,033 | 29.5 | — |
| Tina St. Leger | Option | 8,750 | 29.87 | — |
| Tina St. Leger | Option | 4,168 | 64.53 | — |
| Tina St. Leger | Option | 7,966 | 70.5 | — |
| Tina St. Leger | Option | 23,212 | 29.6 | — |
| David Berman | Option | 8,392 | 24.66 | — |
| David Berman | Option | 28,312 | 64.53 | — |
| David Berman | Option | 62,575 | 70.5 | — |
| David Berman | Option | 129,518 | 29.6 | — |
The Company's compensation program is designed to attract and retain talented and experienced executives to lead successfully, consistent with market practices.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-27 | 29,682,169 | 8,600,029 | 21,642 | 77.54% | Passed |
| 2025 | 2025-05-15 | 27,835,046 | 4,908,015 | 3,359 | 85.01% | Passed |
| 2024 | 2024-05-23 | 33,617,866 | 636,901 | 4,992 | 98.14% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-27 | 77.54%a |
| 2025 | 2025-05-15 | 85.01%b |
| 2024 | 2024-05-23 | 98.14%c |
a. Approved under the standard stated in the filing — “What is an "abstention" and how would it affect the vote? An abstention is not a vote in law and will not be counted in the calculation of the proportion of the votes for or against a particular resolution.”.
b. Approved under the standard stated in the filing — “What is an "abstention" and how would it affect the vote? An abstention is not a vote in law and will not be counted in the calculation of the proportion of the votes for or against a particular resolution.”.
c. Approved under the standard stated in the filing — “What is an "abstention" and how would it affect the vote? An abstention is not a vote in law and will not be counted in the calculation of the proportion of the votes for or against a particular resolution.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 92 : 1 |
|---|---|
| CEO total compensation | $10,885,268 |
| Median employee compensation | $117,720 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Bahija JallalEmployee director | $765,000 | $2,819,992 | $0 | $688,500 | $36,454 | $4,327,446 |
| William PaoIndependent · Audit · Newly elected | 42,466 | — | 799,983 | — | — | 842,449 |
| Professor Sir John BellIndependent · Board Chair · Compensation · Nominating and Corporate Governance (Chair) | 98,952 | 0 | 399,991 | — | 0 | 498,943 |
| Siddharth KaulIndependent · Audit (Chair) · Compensation | 77,500 | 0 | 399,991 | — | 0 | 477,491 |
| Kristine PetersonIndependent · Compensation (Chair) · Nominating and Corporate Governance | 70,000 | 0 | 399,991 | — | 2,541 | 472,532 |
| Roy S. HerbstIndependent · Audit · Compensation | 67,500 | 0 | 399,991 | — | 3,928 | 471,419 |
| Professor Sir Peter RatcliffeIndependent · Audit · Nominating and Corporate Governance | 65,000 | 0 | 399,991 | — | 0 | 464,991 |
| Ranjeev KrishanaIndependent · Compensation · Departed during FY | 51,986 | 0 | 399,991 | — | 0 | 451,977 |
| Robert PerezIndependent · Audit · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Travis CoyIndependent · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 15,000 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,238,404 |
| Equity awards (grant-date value) | $2,819,992 |
| All other compensation | $42,923 |
| Total cost of the board | $4,101,319 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Immunocore Holdings names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Immunocore Holdings.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TG Therapeutics | 2025 | Michael Weiss | $875,000 | $23,550,000 | $0 | $1,146,250 | $25,571,250 |
| 2 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 3 | Apellis Pharmaceuticals | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 4 | Immunocore Holdings | 2025 | Bahija Jallal | 765,000 | 2,819,992 | 6,579,990 | 688,500 | 10,885,268 |
| 5 | Mirium Pharmaceuticals | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 6 | Axsome Therapeutics | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 7 | Intra-Cellular Therapies | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 8 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 9 | IDEAYA Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 10 | Arrowhead Pharmaceuticals | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 11 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 12 | Arvinas | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 13 | Bicycle Therapeutics | 2025 | Kevin Lee | 862,339 | 1,724,800 | 2,961,297 | 543,642 | 6,341,473 |
| 14 | Beam Therapeutics | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 15 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| — | Immatics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Immunocore Holdings | 120% | Options 70 · RSU 30 | not disclosed | Aon |
| Amicus Therapeutics | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arrowhead Pharmaceuticals | 125% | PSU 70 · RSU 30 | not disclosed | Compensia |
| Arvinas | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Axsome Therapeutics | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Beam Therapeutics | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Bicycle Therapeutics | 97% | not disclosed | not disclosed | not disclosed |
| IDEAYA Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Immatics | not disclosed | not disclosed | not disclosed | not disclosed |
| Intra-Cellular Therapies | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis Pharmaceuticals | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Mirium Pharmaceuticals | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| TG Therapeutics | 131% | RSU 100 | No | Compensia, Inc. |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Bahija Jallal | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Summary Compensation Table”. As printed: 10,885,268. Filing ↗machine: r2 · c24 · span 670285–670295 |
| 2 | Section 01, Travis Coy | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Summary Compensation Table”. As printed: 5,171,209. Filing ↗machine: r5 · c24 · span 684079–684088 |
| 3 | Section 01, David Berman | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Summary Compensation Table”. As printed: 4,278,988. Filing ↗machine: r9 · c24 · span 703781–703790 |
| 4 | Section 01, Tina St. Leger | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Summary Compensation Table”. As printed: 1,204,261. Filing ↗machine: t162 · r6 · c24 · span 689496–689505 |
| 5 | Section 03, David Berman RSU | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t170 · r13 · c27 · span 793334–793343 |
| 6 | Section 03, Bahija Jallal RSU | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t170 · r5 · c27 · span 752879–752888 |
| 7 | Section 03, Tina St. Leger RSU | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 778022–778029 |
| 8 | Section 03, Bahija Jallal OPTION | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t170 · r4 · c27 · span 747481–747490 |
| 9 | Section 03, Travis Coy OPTION | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t170 · r7 · c27 · span 763068–763077 |
| 10 | Section 03, David Berman OPTION | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t170 · r12 · c27 · span 788176–788185 |
| 11 | Section 03, Tina St. Leger OPTION | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 773297–773304 |
| 12 | Section 07, pay ratio | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “CEO Pay Ratio”. As printed: 92 : 1. Filing ↗ |
| 13 | Section 08, Bahija Jallal | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 4,327,446. Filing ↗ |
| 14 | Section 08, William Pao | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 842,449. Filing ↗ |
| 15 | Section 08, Professor Sir John Bell | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 498,943. Filing ↗ |
| 16 | Section 08, Siddharth Kaul | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 477,491. Filing ↗ |
| 17 | Section 08, Kristine Peterson | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 472,532. Filing ↗ |
| 18 | Section 08, Roy S. Herbst | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 471,419. Filing ↗ |
| 19 | Section 08, Professor Sir Peter Ratcliffe | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 464,991. Filing ↗ |
| 20 | Section 08, Ranjeev Krishana | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 451,977. Filing ↗ |
| 21 | Section 08, Robert Perez | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 08, Travis Coy | DEF 14A | 2026-04-16 | 0001140361-26-015122 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 02, Roy S. Herbst 2026-05-27 | Form 4 | 2026-05-28 | 0001969520-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Professor Sir John Bell 2026-05-27 | Form 4 | 2026-05-28 | 0001969932-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Siddharth Kaul 2026-05-27 | Form 4 | 2026-05-28 | 0001969522-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Professor Sir Peter Ratcliffe 2026-05-27 | Form 4 | 2026-05-28 | 0001969518-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, William Pao 2026-05-27 | Form 4 | 2026-05-28 | 0001919343-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Kristine Peterson 2026-05-27 | Form 4 | 2026-05-28 | 0001508596-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 06, 2026 vote | Form 8-K | 2026-05-27 | 0001140361-26-022984 | Item 5.07 · say-on-pay result. As reported: 77.54% (votes for as printed: 29,682,169). Filing ↗ |
| 30 | Section 06, 2025 vote | Form 8-K | 2025-05-15 | 0001140361-25-019282 | Item 5.07 · say-on-pay result. As reported: 85.01% (votes for as printed: 27,835,046). Filing ↗ |
| 31 | Section 06, 2024 vote | Form 8-K | 2024-05-23 | 0001140361-24-027312 | Item 5.07 · say-on-pay result. As reported: 98.14% (votes for as printed: 33,617,866). Filing ↗ |
| 32 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 33 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 34 | Section 09b board cost (computed) | Computed | — | — | Cash 1,238,404 + equity 2,819,992 + all other 42,923 = 4,101,319, summed across the director compensation table rows.machine: formula: Σ = 4,101,319 |
| 35 | TG Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001437749-26-014233 | CEO total compensation as printed in TG Therapeutics's own proxy. As printed: 25,571,250. Filing ↗machine: r4 · c24 · span 404551–404561 |
| 36 | Ionis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗ |
| 37 | Apellis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 38 | Immunocore Holdings (subject), Section 10b CEO total | DEF 14A | 2026-04-16 | 0001140361-26-015122 | CEO total compensation as printed in Immunocore Holdings's own proxy. As printed: 10,885,268. Filing ↗machine: r2 · c24 · span 670285–670295 |
| 39 | Mirium Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirium Pharmaceuticals's own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 40 | Axsome Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 41 | Intra-Cellular Therapies, Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 42 | Arcus Biosciences, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 43 | IDEAYA Biosciences, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191501 | CEO total compensation as printed in IDEAYA Biosciences's own proxy. As printed: 9,512,640. Filing ↗machine: r2 · c14 · span 627310–627319 |
| 44 | Arrowhead Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-01-27 | 0000879407-26-000019 | CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484 |
| 45 | Amicus Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 46 | Arvinas, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 47 | Bicycle Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046806 | CEO total compensation as printed in Bicycle Therapeutics's own proxy. As printed: 6,341,473. Filing ↗machine: t83 · r5 · c14 · span 491024–491033 |
| 48 | Beam Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161512 | CEO total compensation as printed in Beam Therapeutics's own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178 |
| 49 | Xencor, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001326732-26-000031 | CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334 |
| 50 | Section 10a, Arrowhead Pharmaceuticals reciprocity | DEF 14A | — | 0000879407-26-000019 | Arrowhead Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 51 | Section 10a, Mirium Pharmaceuticals reciprocity | DEF 14A | — | 0001759425-26-000027 | Mirium Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 52 | Section 10a, IDEAYA Biosciences reciprocity | DEF 14A | — | 0001193125-26-191501 | IDEAYA Biosciences's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 53 | Section 10a, TG Therapeutics reciprocity | DEF 14A | — | 0001437749-26-014233 | TG Therapeutics's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 54 | Section 10a, Xencor reciprocity | DEF 14A | — | 0001326732-26-000031 | Xencor's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 55 | Section 10a, Beam Therapeutics reciprocity | DEF 14A | — | 0001193125-26-161512 | Beam Therapeutics's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 56 | Section 10a, Bicycle Therapeutics reciprocity | DEF 14A | — | 0001558370-25-005258 | Bicycle Therapeutics's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 57 | Section 10a, Ionis Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 58 | Section 10a, Amicus Therapeutics reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 59 | Section 10a, Intra-Cellular Therapies reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 60 | Section 10a, Arvinas reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 61 | Section 10a, Axsome Therapeutics reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
| 62 | Section 10a, Apellis Pharmaceuticals reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Immunocore Holdings. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.